Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.

Sirolimus-coated balloon angioplasty reduces major adverse limb events by 4.9 percentage points compared to uncoated balloons in infrainguinal artery disease patients.

• Why it matters: Infrainguinal artery disease often leads to limb loss and reinterventions, but the effectiveness of drug-coated balloons in reducing these adverse outcomes remains uncertain.
• What they did: A randomized trial involving 1252 patients compared sirolimus-coated balloons to uncoated balloons, assessing limb-related adverse events and safety over one year.
• The result: Sirolimus-coated balloons significantly lowered the incidence of major limb events and revascularizations without increasing death or adverse events, supporting their use for better limb preservation.